You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFurazolidone
Accession NumberDB00614  (APRD00988)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone binds bacterial DNA which leads to the gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514)
Structure
Thumb
Synonyms
3-(5'-Nitrofurfuralamino)-2-oxazolidone
3-[(5-Nitrofurfurylidene)amino]-2-oxazolidinone
3-[(5-Nitrofurfurylidene)amino]-2-oxazolidone
3-[(5-Nitrofurylidene)amino]-2-oxazolidone
3-{[(5-nitro-2-furanyl)methylene]amino}-2-oxazolidinone
5-Nitro-N-(2-oxo-3-oxazolidinyl)-2-furanmethanimine
Furazolidona
Furazolidone
Furazolidonum
Furoxone
FZL
N-(5-Nitro-2-furfurylidene)-3-amino-2-oxazolidone
N-(5-Nitro-2-furfurylidene)-3-aminooxazolidine-2-one
Nitrofurazolidone
Nitrofurazolidonum
External Identifiers
  • USAF EA-1
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Dependal-MGlaxoSmithKline
FuroxoneRoberts Laboratories
Brand mixturesNot Available
SaltsNot Available
Categories
UNII5J9CPU3RE0
CAS number67-45-8
WeightAverage: 225.1583
Monoisotopic: 225.038570349
Chemical FormulaC8H7N3O5
InChI KeyInChIKey=PLHJDBGFXBMTGZ-WEVVVXLNSA-N
InChI
InChI=1S/C8H7N3O5/c12-8-10(3-4-15-8)9-5-6-1-2-7(16-6)11(13)14/h1-2,5H,3-4H2/b9-5+
IUPAC Name
3-{[(5-nitrofuran-2-yl)methylidene]amino}-1,3-oxazolidin-2-one
SMILES
[O-][N+](=O)C1=CC=C(O1)C=NN1CCOC1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as nitrofurans. These are compounds containing a furan ring which bears a nitro group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassFurans
Sub ClassNitrofurans
Direct ParentNitrofurans
Alternative Parents
Substituents
  • 2-nitrofuran
  • Oxazolidinone
  • Heteroaromatic compound
  • Organic nitro compound
  • Organic nitrite
  • C-nitro compound
  • Oxacycle
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Allyl-type 1,3-dipolar organic compound
  • Organic oxoazanium
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Organonitrogen compound
  • Organic cation
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the specific and symptomatic treatment of bacterial or protozoal diarrhea and enteritis caused by susceptible organisms.
PharmacodynamicsFuroxone has a broad antibacterial spectrum covering the majority of gastrointestinal tract pathogens including E. coli, staphylococci, Salmonella, Shigella, Proteus, Aerobacter aerogenes, Vibrio cholerae and Giardia lamblia. Its bactericidal activity is based upon its interference with DNA replication and protein production; this antimicrobial action minimizes the development of resistant organisms.
Mechanism of actionFurazolidone and its related free radical products are believed to bind DNA and induce cross-links. Bacterial DNA is particularly susceptible to this drug leading to high levels of mutations (transitions and transversions) in the bacterial chromosome.
Related Articles
AbsorptionRadiolabeled drug studies indicate that furazolidone is well absorbed following oral administration
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Furazolidone is rapidly and extensively metabolized; the primary metabolic pathway identified begins with nitro-reduction to the aminofuran derivative. Two major metabolites are produced: 3-amino-2-oxazolidone (AOZ) or beta-hydroxyethylhydrazine (HEH). AOZ is responsible for monoamine oxidase inhibition. Detoxification and elimination of the drug is done primarily by conjugation with glutathione.

SubstrateEnzymesProduct
Furazolidone
Not Available
beta-HydroxyethylhydrazineDetails
Furazolidone
Not Available
3-amino-2-oxazolidoneDetails
Route of eliminationNot Available
Half life10 minutes
ClearanceNot Available
ToxicityReactions to Furoxone have been reported including a fall in blood pressure, urticaria, fever, arthralgia, and a vesicular morbilliform rash. Other adverse effects can include a brown discoloration of the urine; hemolysis can occur in G6PDH-deficient patients. The drug has a monoamine oxidase (MAO) inhibitory effect and should never be given concurrently to individuals already taking MAO inhibitors.
Affected organisms
  • Microbes (bacteria, parasites)
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9038
Blood Brain Barrier+0.9117
Caco-2 permeable-0.5736
P-glycoprotein substrateNon-substrate0.7829
P-glycoprotein inhibitor INon-inhibitor0.7761
P-glycoprotein inhibitor IINon-inhibitor0.9597
Renal organic cation transporterNon-inhibitor0.8351
CYP450 2C9 substrateNon-substrate0.8117
CYP450 2D6 substrateNon-substrate0.8415
CYP450 3A4 substrateSubstrate0.5984
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9134
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.928
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8828
Ames testAMES toxic0.9108
CarcinogenicityNon-carcinogens0.9097
BiodegradationReady biodegradable0.8978
Rat acute toxicity2.1639 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7889
hERG inhibition (predictor II)Non-inhibitor0.9057
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Shire development inc
Packagers
  • Professional Co.
Dosage formsNot Available
Prices
Unit descriptionCostUnit
Furazolidone powder2.04USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point254-256Drake, G.D., Gever, G. and Hayes, K.J.; U.S. Patent 2,759,931; August 21, 1956; assigned to The Norwich Pharmacal Company. Gever, G. and O'Keefe, C.J.; U.S. Patent 2,927,l IO; March 1, 1960; assigned to The Norwich Pharmacal Company
water solubility40 mg/L (at 25 °C)MERCK INDEX (1996); pH 6
logP-0.04DEBNATH,AK ET AL. (1991)
Predicted Properties
PropertyValueSource
Water Solubility0.364 mg/mLALOGPS
logP0.15ALOGPS
logP0.87ChemAxon
logS-2.8ALOGPS
pKa (Strongest Basic)-2.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area100.86 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity51.09 m3·mol-1ChemAxon
Polarizability19.74 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Drake, G.D., Gever, G. and Hayes, K.J.; U.S. Patent 2,759,931; August 21, 1956; assigned to The Norwich Pharmacal Company.
Gever, G. and O’Keefe, C.J.; U.S. Patent 2,927,l IO; March 1, 1960; assigned to The Norwich Pharmacal Company.

US2742462
General ReferencesNot Available
External Links
ATC CodesG01AX06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (74.1 KB)
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineFurazolidone may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineFurazolidone may increase the hypertensive activities of 3,4-Methylenedioxymethamphetamine.
AcarboseFurazolidone may increase the hypoglycemic activities of Acarbose.
AcebutololFurazolidone may increase the hypotensive activities of Acebutolol.
AlbiglutideFurazolidone may increase the hypoglycemic activities of Albiglutide.
AliskirenFurazolidone may increase the hypotensive activities of Aliskiren.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Furazolidone.
AlogliptinFurazolidone may increase the hypoglycemic activities of Alogliptin.
AlprenololFurazolidone may increase the hypotensive activities of Alprenolol.
AltretamineAltretamine may increase the orthostatic hypotensive activities of Furazolidone.
AmbrisentanFurazolidone may increase the hypotensive activities of Ambrisentan.
AmineptineFurazolidone may increase the serotonergic activities of Amineptine.
AmitriptylineFurazolidone may increase the serotonergic activities of Amitriptyline.
AmlodipineFurazolidone may increase the hypotensive activities of Amlodipine.
AmoxapineFurazolidone may increase the serotonergic activities of Amoxapine.
AmphetamineFurazolidone may increase the hypertensive activities of Amphetamine.
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Furazolidone.
ApraclonidineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Apraclonidine.
ArbutamineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Arbutamine.
ArformoterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Arformoterol.
AtenololFurazolidone may increase the hypotensive activities of Atenolol.
AtomoxetineFurazolidone may increase the central neurotoxic activities of Atomoxetine.
AtropineFurazolidone may increase the hypertensive activities of Atropine.
BambuterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Bambuterol.
BenazeprilFurazolidone may increase the hypotensive activities of Benazepril.
BendroflumethiazideFurazolidone may increase the hypotensive activities of Bendroflumethiazide.
BenzphetamineFurazolidone may increase the hypertensive activities of Benzphetamine.
BepridilFurazolidone may increase the hypotensive activities of Bepridil.
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Furazolidone.
BetaxololFurazolidone may increase the hypotensive activities of Betaxolol.
BethanidineFurazolidone may increase the hypotensive activities of Bethanidine.
BezafibrateThe risk or severity of adverse effects can be increased when Furazolidone is combined with Bezafibrate.
BimatoprostFurazolidone may increase the hypotensive activities of Bimatoprost.
BisoprololFurazolidone may increase the hypotensive activities of Bisoprolol.
BosentanFurazolidone may increase the hypotensive activities of Bosentan.
BretyliumFurazolidone may increase the hypotensive activities of Bretylium.
BrimonidineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Brimonidine.
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Furazolidone.
BupranololFurazolidone may increase the hypotensive activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Furazolidone.
BupropionFurazolidone may increase the hypertensive activities of Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Furazolidone.
CabergolineThe metabolism of Cabergoline can be decreased when combined with Furazolidone.
CanagliflozinFurazolidone may increase the hypoglycemic activities of Canagliflozin.
CandesartanFurazolidone may increase the hypotensive activities of Candesartan.
CandoxatrilFurazolidone may increase the hypotensive activities of Candoxatril.
CaptoprilFurazolidone may increase the hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Furazolidone.
CarteololFurazolidone may increase the hypotensive activities of Carteolol.
CarvedilolFurazolidone may increase the hypotensive activities of Carvedilol.
CeliprololFurazolidone may increase the hypotensive activities of Celiprolol.
ChlorothiazideFurazolidone may increase the hypotensive activities of Chlorothiazide.
ChlorphentermineFurazolidone may increase the hypertensive activities of Chlorphentermine.
ChlorpropamideFurazolidone may increase the hypoglycemic activities of Chlorpropamide.
ChlorthalidoneFurazolidone may increase the hypotensive activities of Chlorthalidone.
CilazaprilFurazolidone may increase the hypotensive activities of Cilazapril.
CirazolineFurazolidone may increase the hypertensive activities of Cirazoline.
CitalopramFurazolidone may increase the serotonergic activities of Citalopram.
ClemastineFurazolidone may increase the anticholinergic activities of Clemastine.
ClenbuterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Clenbuterol.
ClomipramineFurazolidone may increase the serotonergic activities of Clomipramine.
ClonidineFurazolidone may increase the hypotensive activities of Clonidine.
CryptenamineFurazolidone may increase the hypotensive activities of Cryptenamine.
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Furazolidone.
CyclothiazideFurazolidone may increase the hypotensive activities of Cyclothiazide.
CyproheptadineFurazolidone may increase the anticholinergic activities of Cyproheptadine.
DapagliflozinFurazolidone may increase the hypoglycemic activities of Dapagliflozin.
DapoxetineFurazolidone may increase the serotonergic activities of Dapoxetine.
DebrisoquinFurazolidone may increase the hypotensive activities of Debrisoquin.
DeserpidineFurazolidone may increase the hypotensive activities of Deserpidine.
DesipramineFurazolidone may increase the serotonergic activities of Desipramine.
DesvenlafaxineFurazolidone may increase the serotonergic activities of Desvenlafaxine.
DexmethylphenidateFurazolidone may increase the hypertensive activities of Dexmethylphenidate.
DextroamphetamineFurazolidone may increase the hypertensive activities of Dextroamphetamine.
DextromethorphanFurazolidone may increase the serotonergic activities of Dextromethorphan.
DiazoxideFurazolidone may increase the hypotensive activities of Diazoxide.
DiethylpropionFurazolidone may increase the hypertensive activities of Diethylpropion.
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Furazolidone.
DiltiazemFurazolidone may increase the hypotensive activities of Diltiazem.
DipivefrinThe risk or severity of adverse effects can be increased when Furazolidone is combined with Dipivefrin.
DisopyramideFurazolidone may increase the hypoglycemic activities of Disopyramide.
DobutamineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Dobutamine.
DomperidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Domperidone.
DorzolamideFurazolidone may increase the hypotensive activities of Dorzolamide.
DosulepinFurazolidone may increase the serotonergic activities of Dosulepin.
DoxapramFurazolidone may increase the hypertensive activities of Doxapram.
DoxazosinFurazolidone may increase the hypotensive activities of Doxazosin.
DoxepinFurazolidone may increase the serotonergic activities of Doxepin.
DoxylamineFurazolidone may increase the anticholinergic activities of Doxylamine.
DroxidopaThe risk or severity of adverse effects can be increased when Furazolidone is combined with Droxidopa.
DulaglutideFurazolidone may increase the hypoglycemic activities of Dulaglutide.
DuloxetineFurazolidone may increase the serotonergic activities of Duloxetine.
EfonidipineFurazolidone may increase the hypotensive activities of Efonidipine.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Furazolidone.
EmpagliflozinFurazolidone may increase the hypoglycemic activities of Empagliflozin.
EnalaprilFurazolidone may increase the hypotensive activities of Enalapril.
EnalaprilatFurazolidone may increase the hypotensive activities of Enalaprilat.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Furazolidone.
EphedraThe risk or severity of adverse effects can be increased when Furazolidone is combined with Ephedra.
EpinephrineFurazolidone may increase the hypertensive activities of Epinephrine.
EpoprostenolFurazolidone may increase the hypotensive activities of Epoprostenol.
EprosartanFurazolidone may increase the hypotensive activities of Eprosartan.
ErgotamineFurazolidone may increase the hypertensive activities of Ergotamine.
EscitalopramFurazolidone may increase the serotonergic activities of Escitalopram.
EsmirtazapineFurazolidone may increase the serotonergic activities of Esmirtazapine.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Furazolidone.
EtoperidoneFurazolidone may increase the serotonergic activities of Etoperidone.
ExenatideFurazolidone may increase the hypoglycemic activities of Exenatide.
FelodipineFurazolidone may increase the hypotensive activities of Felodipine.
FenfluramineFurazolidone may increase the serotonergic activities of Fenfluramine.
FenoldopamFurazolidone may increase the hypotensive activities of Fenoldopam.
FenoterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Fenoterol.
FluoxetineFurazolidone may increase the serotonergic activities of Fluoxetine.
FluvoxamineFurazolidone may increase the serotonergic activities of Fluvoxamine.
FormoterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Formoterol.
FosinoprilFurazolidone may increase the hypotensive activities of Fosinopril.
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Furazolidone.
GliclazideFurazolidone may increase the hypoglycemic activities of Gliclazide.
GlimepirideFurazolidone may increase the hypoglycemic activities of Glimepiride.
GlipizideFurazolidone may increase the hypoglycemic activities of Glipizide.
GlyburideFurazolidone may increase the hypoglycemic activities of Glyburide.
GuanabenzFurazolidone may increase the hypotensive activities of Guanabenz.
GuanadrelFurazolidone may increase the hypotensive activities of Guanadrel.
GuanethidineFurazolidone may increase the hypotensive activities of Guanethidine.
GuanfacineFurazolidone may increase the hypotensive activities of Guanfacine.
HexamethoniumFurazolidone may increase the hypotensive activities of Hexamethonium.
HydralazineFurazolidone may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideFurazolidone may increase the hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Hydrocodone.
HydroflumethiazideFurazolidone may increase the hypotensive activities of Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Hydromorphone.
Hydroxyamphetamine hydrobromideFurazolidone may increase the hypertensive activities of Hydroxyamphetamine hydrobromide.
ImipramineFurazolidone may increase the serotonergic activities of Imipramine.
IndacaterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Indacaterol.
IndalpineFurazolidone may increase the serotonergic activities of Indalpine.
IndapamideFurazolidone may increase the hypotensive activities of Indapamide.
IndenololFurazolidone may increase the hypotensive activities of Indenolol.
IndoraminFurazolidone may increase the hypotensive activities of Indoramin.
Insulin AspartFurazolidone may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirFurazolidone may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineFurazolidone may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineFurazolidone may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanFurazolidone may increase the hypoglycemic activities of Insulin Human.
Insulin LisproFurazolidone may increase the hypoglycemic activities of Insulin Lispro.
IrbesartanFurazolidone may increase the hypotensive activities of Irbesartan.
IsoetarineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Isoetarine.
IsomethepteneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Isometheptene.
IsoprenalineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Isoprenaline.
IsradipineFurazolidone may increase the hypotensive activities of Isradipine.
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Furazolidone.
LabetalolFurazolidone may increase the hypotensive activities of Labetalol.
LacidipineFurazolidone may increase the hypotensive activities of Lacidipine.
LanreotideFurazolidone may increase the hypoglycemic activities of Lanreotide.
LatanoprostFurazolidone may increase the hypotensive activities of Latanoprost.
LercanidipineFurazolidone may increase the hypotensive activities of Lercanidipine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Furazolidone.
LevomilnacipranFurazolidone may increase the serotonergic activities of Levomilnacipran.
LevonordefrinFurazolidone may increase the hypertensive activities of Levonordefrin.
LinezolidThe risk or severity of adverse effects can be increased when Furazolidone is combined with Linezolid.
LiraglutideFurazolidone may increase the hypoglycemic activities of Liraglutide.
LisdexamfetamineFurazolidone may increase the hypertensive activities of Lisdexamfetamine.
LisinoprilFurazolidone may increase the hypotensive activities of Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Furazolidone.
LithiumThe risk or severity of adverse effects can be increased when Furazolidone is combined with Lithium.
LofexidineFurazolidone may increase the hypotensive activities of Lofexidine.
LosartanFurazolidone may increase the hypotensive activities of Losartan.
Lu AA21004Furazolidone may increase the serotonergic activities of Lu AA21004.
MacitentanFurazolidone may increase the hypotensive activities of Macitentan.
ManidipineFurazolidone may increase the hypotensive activities of Manidipine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Furazolidone.
MecamylamineFurazolidone may increase the hypotensive activities of Mecamylamine.
MecaserminFurazolidone may increase the hypoglycemic activities of Mecasermin.
MephentermineFurazolidone may increase the hypertensive activities of Mephentermine.
MequitazineFurazolidone may increase the anticholinergic activities of Mequitazine.
MetaraminolFurazolidone may increase the hypertensive activities of Metaraminol.
MetforminFurazolidone may increase the hypoglycemic activities of Metformin.
MethadoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Methadone.
MethamphetamineFurazolidone may increase the hypertensive activities of Methamphetamine.
MethoxamineFurazolidone may increase the hypertensive activities of Methoxamine.
MethyldopaThe risk or severity of adverse effects can be increased when Furazolidone is combined with Methyldopa.
Methylene blueFurazolidone may increase the serotonergic activities of Methylene blue.
MethylphenidateFurazolidone may increase the hypertensive activities of Methylphenidate.
MetipranololFurazolidone may increase the hypotensive activities of Metipranolol.
MetolazoneFurazolidone may increase the hypotensive activities of Metolazone.
MetoprololFurazolidone may increase the hypotensive activities of Metoprolol.
MianserinFurazolidone may increase the neurotoxic activities of Mianserin.
MibefradilFurazolidone may increase the hypotensive activities of Mibefradil.
MidodrineFurazolidone may increase the hypertensive activities of Midodrine.
MifepristoneFurazolidone may increase the hypoglycemic activities of Mifepristone.
MiglitolFurazolidone may increase the hypoglycemic activities of Miglitol.
MilnacipranFurazolidone may increase the serotonergic activities of Milnacipran.
MinoxidilFurazolidone may increase the hypotensive activities of Minoxidil.
MirtazapineFurazolidone may increase the central neurotoxic activities of Mirtazapine.
MoclobemideThe risk or severity of adverse effects can be increased when Furazolidone is combined with Moclobemide.
MoexiprilFurazolidone may increase the hypotensive activities of Moexipril.
MorphineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Morphine.
MoxonidineFurazolidone may increase the hypotensive activities of Moxonidine.
NadololFurazolidone may increase the hypotensive activities of Nadolol.
NaratriptanThe metabolism of Naratriptan can be decreased when combined with Furazolidone.
NateglinideFurazolidone may increase the hypoglycemic activities of Nateglinide.
NebivololFurazolidone may increase the hypotensive activities of Nebivolol.
NicardipineFurazolidone may increase the hypotensive activities of Nicardipine.
NicorandilFurazolidone may increase the hypotensive activities of Nicorandil.
NiguldipineFurazolidone may increase the hypotensive activities of Niguldipine.
NilvadipineFurazolidone may increase the hypotensive activities of Nilvadipine.
NimodipineFurazolidone may increase the hypotensive activities of Nimodipine.
NisoldipineFurazolidone may increase the hypotensive activities of Nisoldipine.
NitrendipineFurazolidone may increase the hypotensive activities of Nitrendipine.
NitroprussideFurazolidone may increase the hypotensive activities of Nitroprusside.
NorepinephrineFurazolidone may increase the hypertensive activities of Norepinephrine.
NortriptylineFurazolidone may increase the serotonergic activities of Nortriptyline.
OctreotideFurazolidone may increase the hypoglycemic activities of Octreotide.
OlanzapineFurazolidone may increase the serotonergic activities of Olanzapine.
OlmesartanFurazolidone may increase the hypotensive activities of Olmesartan.
OlodaterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Olodaterol.
OmapatrilatFurazolidone may increase the hypotensive activities of Omapatrilat.
OrciprenalineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Orciprenaline.
OxprenololFurazolidone may increase the hypotensive activities of Oxprenolol.
OxycodoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Furazolidone.
PargylineFurazolidone may increase the hypotensive activities of Pargyline.
ParoxetineFurazolidone may increase the serotonergic activities of Paroxetine.
PasireotideFurazolidone may increase the hypoglycemic activities of Pasireotide.
PenbutololFurazolidone may increase the hypotensive activities of Penbutolol.
PentamidineFurazolidone may increase the hypoglycemic activities of Pentamidine.
PentoliniumFurazolidone may increase the hypotensive activities of Pentolinium.
PergolideThe metabolism of Pergolide can be decreased when combined with Furazolidone.
PerindoprilFurazolidone may increase the hypotensive activities of Perindopril.
PethidineFurazolidone may increase the serotonergic activities of Pethidine.
PhenoxybenzamineFurazolidone may increase the hypotensive activities of Phenoxybenzamine.
PhentermineFurazolidone may increase the hypertensive activities of Phentermine.
PhentolamineFurazolidone may increase the hypotensive activities of Phentolamine.
PhenylephrineFurazolidone may increase the hypertensive activities of Phenylephrine.
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Phenylpropanolamine.
PholcodinePholcodine may increase the serotonergic activities of Furazolidone.
PinacidilFurazolidone may increase the hypotensive activities of Pinacidil.
PindololFurazolidone may increase the hypotensive activities of Pindolol.
PioglitazoneFurazolidone may increase the hypoglycemic activities of Pioglitazone.
PirbuterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Pirbuterol.
PizotifenFurazolidone may increase the anticholinergic activities of Pizotifen.
PolythiazideFurazolidone may increase the hypotensive activities of Polythiazide.
PramlintideFurazolidone may increase the hypoglycemic activities of Pramlintide.
PrazosinFurazolidone may increase the hypotensive activities of Prazosin.
ProcaterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Procaterol.
PropranololFurazolidone may increase the hypotensive activities of Propranolol.
ProtriptylineFurazolidone may increase the serotonergic activities of Protriptyline.
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Furazolidone.
QuinaprilFurazolidone may increase the hypotensive activities of Quinapril.
QuinineFurazolidone may increase the hypoglycemic activities of Quinine.
RamiprilFurazolidone may increase the hypotensive activities of Ramipril.
RemikirenFurazolidone may increase the hypotensive activities of Remikiren.
RepaglinideFurazolidone may increase the hypoglycemic activities of Repaglinide.
RescinnamineFurazolidone may increase the hypotensive activities of Rescinnamine.
ReserpineFurazolidone may increase the hypotensive activities of Reserpine.
RiociguatFurazolidone may increase the hypotensive activities of Riociguat.
RitodrineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Ritodrine.
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Furazolidone.
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Furazolidone.
RosiglitazoneFurazolidone may increase the hypoglycemic activities of Rosiglitazone.
SalbutamolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Salbutamol.
SalmeterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Salmeterol.
SaprisartanFurazolidone may increase the hypotensive activities of Saprisartan.
SaxagliptinFurazolidone may increase the hypoglycemic activities of Saxagliptin.
SelexipagFurazolidone may increase the hypotensive activities of Selexipag.
SertralineFurazolidone may increase the serotonergic activities of Sertraline.
SitagliptinFurazolidone may increase the hypoglycemic activities of Sitagliptin.
SitaxentanFurazolidone may increase the hypotensive activities of Sitaxentan.
SpiraprilFurazolidone may increase the hypotensive activities of Spirapril.
SulfadiazineFurazolidone may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleFurazolidone may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazoleFurazolidone may increase the hypoglycemic activities of Sulfisoxazole.
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Furazolidone.
SunitinibFurazolidone may increase the hypoglycemic activities of Sunitinib.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Furazolidone.
TelmisartanFurazolidone may increase the hypotensive activities of Telmisartan.
TemocaprilFurazolidone may increase the hypotensive activities of Temocapril.
TerbutalineThe risk or severity of adverse effects can be increased when Furazolidone is combined with Terbutaline.
TerlipressinFurazolidone may increase the hypotensive activities of Terlipressin.
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Furazolidone.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Furazolidone.
TetryzolineFurazolidone may increase the hypertensive activities of Tetryzoline.
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Furazolidone.
TianeptineFurazolidone may increase the serotonergic activities of Tianeptine.
TiboloneFurazolidone may increase the hypotensive activities of Tibolone.
TicrynafenFurazolidone may increase the hypotensive activities of Ticrynafen.
TimololFurazolidone may increase the hypotensive activities of Timolol.
TolazamideFurazolidone may increase the hypoglycemic activities of Tolazamide.
TolazolineFurazolidone may increase the hypotensive activities of Tolazoline.
TolbutamideFurazolidone may increase the hypoglycemic activities of Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Furazolidone.
TorasemideFurazolidone may increase the hypotensive activities of Torasemide.
TramadolTramadol may increase the neuroexcitatory activities of Furazolidone.
TrandolaprilFurazolidone may increase the hypotensive activities of Trandolapril.
TravoprostFurazolidone may increase the hypotensive activities of Travoprost.
TrazodoneFurazolidone may increase the serotonergic activities of Trazodone.
TreprostinilFurazolidone may increase the hypotensive activities of Treprostinil.
TrichlormethiazideFurazolidone may increase the hypotensive activities of Trichlormethiazide.
TrimazosinFurazolidone may increase the hypotensive activities of Trimazosin.
TrimethaphanFurazolidone may increase the hypotensive activities of Trimethaphan.
TrimipramineFurazolidone may increase the serotonergic activities of Trimipramine.
UnoprostoneFurazolidone may increase the hypotensive activities of Unoprostone.
ValsartanFurazolidone may increase the hypotensive activities of Valsartan.
VenlafaxineFurazolidone may increase the serotonergic activities of Venlafaxine.
VilanterolThe risk or severity of adverse effects can be increased when Furazolidone is combined with Vilanterol.
VilazodoneFurazolidone may increase the serotonergic activities of Vilazodone.
VortioxetineFurazolidone may increase the serotonergic activities of Vortioxetine.
XylometazolineFurazolidone may increase the hypotensive activities of Xylometazoline.
ZimelidineFurazolidone may increase the serotonergic activities of Zimelidine.
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Furazolidone.
Food InteractionsNot Available

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
yes
Actions
cross-linking/alkylation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Meng J, Mangat SS, Grudzinski IP, Law FC: Evidence of 14C-furazolidone metabolite binding to the hepatic DNA of trout. Drug Metabol Drug Interact. 1998;14(4):209-19. [PubMed:10694929 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Primary amine oxidase activity
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
Gene Name:
MAOB
Uniprot ID:
P27338
Molecular Weight:
58762.475 Da
References
  1. Timperio AM, Kuiper HA, Zolla L: Identification of a furazolidone metabolite responsible for the inhibition of amino oxidases. Xenobiotica. 2003 Feb;33(2):153-67. [PubMed:12623758 ]
  2. Ali BH: Pharmacological, therapeutic and toxicological properties of furazolidone: some recent research. Vet Res Commun. 1999 Oct;23(6):343-60. [PubMed:10543364 ]
  3. Hoogenboom LA, Tomassini O, Oorsprong MB, Kuiper HA: Use of pig hepatocytes to study the inhibition of monoamine oxidase by furazolidone. Food Chem Toxicol. 1991 Mar;29(3):185-91. [PubMed:2032659 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Serotonin binding
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
Gene Name:
MAOA
Uniprot ID:
P21397
Molecular Weight:
59681.27 Da
References
  1. Timperio AM, Kuiper HA, Zolla L: Identification of a furazolidone metabolite responsible for the inhibition of amino oxidases. Xenobiotica. 2003 Feb;33(2):153-67. [PubMed:12623758 ]
  2. Ali BH: Pharmacological, therapeutic and toxicological properties of furazolidone: some recent research. Vet Res Commun. 1999 Oct;23(6):343-60. [PubMed:10543364 ]
  3. Hoogenboom LA, Tomassini O, Oorsprong MB, Kuiper HA: Use of pig hepatocytes to study the inhibition of monoamine oxidase by furazolidone. Food Chem Toxicol. 1991 Mar;29(3):185-91. [PubMed:2032659 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23